Clinical trials: Brain Structure
Alzheimer's Disease, Lewy Body Dementia
Pulsed Electromagnetic Field Treatment With Dementia Patients
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices.
- Conditions
- Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
- Trial name
- NCT06862557
- Testing
- ECHS AD Device
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Herrick Medical LLC
Phenylketonurias, PKU
Evaluation of PKU Sphere in Italy
20 participants with PKU will build-up their dietary intake of PKU sphere over 2-16 weeks, depending on their level of metabolic control whilst doing so.
- Trial name
- NCT04679467
- Testing
- PKU sphere
- Where
- 4 sites in Italy
- Volunteers
- 13 people
- Sponsor
- Vitaflo International, Ltd
Epilepsy, Idiopathic Generalized Epilepsy
RNS System NAUTILUS Study
To demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant…
- Conditions
- Epilepsy, Idiopathic Generalized Epilepsy, Generalized Tonic Clonic Seizure
- Trial name
- NAUTILUS (NCT05147571)
- Testing
- Responsive stimulation
- Where
- 23 sites in United States
- Volunteers
- 100 people
- Sponsor
- NeuroPace
Epilepsy, Focal Seizures
A Study of GWP42006 in People With Focal Seizures - Part A
To evaluate the pharmacokinetics, safety and tolerability of GWP42006 compared with placebo, in the presence of other antiepileptic drugs (AEDs).
- Trial name
- NCT02369471
- Testing
- GWP42006
- Where
- 9 sites in Czechia, Spain and 1 more
- Volunteers
- 32 people
- Sponsor
- Jazz Pharmaceuticals
OTC Deficiency
Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency
The primary objective is to evaluate the efficacy of DTX301 on the improvement of ornithine transcarbamylase (OTC) function by maintaining safe plasma ammonia levels.
- Trial name
- NCT05345171
- Testing
- DTX301, Oral Corticosteroids, Sodium Acetate
- Where
- 16 sites in United States, Argentina and 8 more
- Volunteers
- 37 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Parkinson Disease
Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients
This study is implemented to identify factors having an impact on improvement or exacerbation of non-motor symptoms, to provide information contributing to development of medical care in this field and improvement of patients'…
- Trial name
- J-FIRST (NCT02073981)
- Where
- Japan
- Volunteers
- 1,021 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.
- Trial name
- EXIST-2 (NCT00790400)
- Testing
- Everolimus (RAD001)
- Where
- 25 sites in United States, Canada and 9 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
Study of Valproate in Young Patients Suffering From Epilepsy
Main objective: Therapeutic follow-up study Evaluate the clinical and biological safety of valproate administered as microgranules, under standard prescription conditions, with therapeutic follow-up and individual dosage…
- Trial name
- VAPOP (NCT00385411)
- Testing
- valproate microgranules
- Where
- France
- Volunteers
- 81 people
- Sponsor
- Sanofi
Epilepsy
Pharmacokinetics, Efficacy and Tolerability of BIA 2-093
The purpose of this study is to characterize the pharmacokinetics of Eslicarbazepine acetate in children and adolescents with epilepsy.
- Trial name
- NCT02170064
- Testing
- BIA 2-093 (Eslicarbazepine acetate)
- Where
- Romania
- Volunteers
- 35 people
- Sponsor
- Bial - Portela C S.A.
Cerebrovascular Accident
Anti-MAG First Administration to Human
GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein (MAG), a protein that inhibits axonal regeneration.
- Trial name
- NCT00622609
- Testing
- GSK249320A
- Where
- 2 sites in United States, Australia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Migraine
Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine
The purpose of the study is to evaluate the treatment satisfaction of subjects using Sumavel DosePro to treat their moderate to severe migraines.
- Trial name
- NCT01016834
- Testing
- Sumavel DosePro, Sumatriptan
- Where
- 21 sites in United States
- Volunteers
- 246 people
- Sponsor
- Zogenix, Inc.
Migraine Disorders, Chronic Migraine Headache
EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine
EMBRACE-OBS is the first phase of the EMBRACE research program. This single-site observational registry accesses and analyzes patient-reported outcome data already collected through routine clinical care from adults with migraine…
- Conditions
- Migraine Disorders, Chronic Migraine Headache, Migraine
- Trial name
- EMBRACE-OBS (NCT07652034)
- Testing
- Middle Meningeal Artery Embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cortex Neurovascular
Hereditary Tyrosinemia, Type I
Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)
The purpose of this study is to compare the bioavailability of the Test Product, Nitisinone 10 mg Tablet, under fasting and fed conditions (food-effect).
- Trial name
- NCT02750332
- Testing
- Nitisinone
- Where
- South Africa
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cycle Pharmaceuticals Ltd.
Asymptomatic Amyloid-positive
An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
The purpose of this study is to evaluate whether treatment with atabecestat slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite…
- Trial name
- EARLY (NCT02569398)
- Testing
- Atabecestat, 5 mg, Atabecestat, 25 mg
- Where
- 128 sites in United States, Australia and 11 more
- Volunteers
- 557 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Parkinson's Disease
Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients
This is a randomized, placebo-controlled, parallel group, patient-blind, single-center phase I clinical trial of repeated once every 4 weeks administration by subcutaneous injection of AFFITOPE® PD01A, adsorbed to aluminium oxide…
- Trial name
- NCT02758730
- Testing
- AFFITOPE® PD01A + Adjuvant, Adjuvant without active component
- Where
- Germany
- Sponsor
- Affiris AG
Glycogen Storage Disease Type II, Pompe Disease
Pompe Disease Registry Protocol
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both…
- Trial name
- NCT00231400
- Where
- 282 sites in United States, Argentina and 42 more
- Volunteers
- 2,000 people
- Sponsor
- Genzyme, a Sanofi Company
Alzheimer's Disease
Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease
The purpose of this study is to investigate efficacy and safety of different doses of AC-3933 in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00359944
- Testing
- AC-3933, Sugar Pill
- Where
- 34 sites in United States
- Volunteers
- 171 people
- Sponsor
- Sumitomo Pharma America, Inc.
Alzheimer's Disease
Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease
This is a single-center, double-blind, inpatient study followed by an outpatient, placebo-controlled, multiple-IV injection evaluation of the safety and tolerability of PPI-1019 in subjects with mild-moderate Alzheimer's disease…
- Trial name
- NCT00100334
- Testing
- PPI-1019 (APAN)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- PRAECIS Pharmaceuticals Inc.
Alzheimer Disease
ANAVEX2-73 for Treatment of Early Alzheimer's Disease
Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. Additional outcome measures include refined measures of sleep, behavioral and psychological symptoms…
- Trial name
- NCT03790709
- Testing
- High dose ANAVEX2-73, Mid dose ANAVEX2-73
- Where
- 54 sites in Australia, Canada and 3 more
- Volunteers
- 509 people
- Sponsor
- Anavex Life Sciences Corp.
Parkinson Disease
A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)
The purpose of the study is to investigate the incidences of psychiatric symptoms (example, hallucinations), somnolence and sudden onset of sleep, dyskinesia, and retinal degeneration-related events during treatment with Equfina…
- Trial name
- NCT04724109
- Testing
- Equfina
- Where
- 2 sites in Japan
- Volunteers
- 1,088 people
- Sponsor
- Eisai Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.